Atea Pharmaceuticals Misses Q1 Earnings Estimates

Biotech firm's stock price rises despite disappointing results

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Atea Pharmaceuticals (NASDAQ:AVIR), a clinical-stage biopharmaceutical company focused on developing oral antiviral therapies, reported its first quarter 2026 financial results on Thursday. The company reported a loss of $0.57 per share, missing analysts' consensus estimate of a $0.49 per share loss.

Why it matters

Atea Pharmaceuticals is considered a key player in the race to develop effective COVID-19 treatments. While the company's stock price rose on the earnings news, the miss on earnings expectations could raise concerns about the progress of Atea's drug development pipeline.

The details

Atea Pharmaceuticals reported a net loss of $44.7 million, or $0.57 per share, for the first quarter of 2026. This compares to a net loss of $38.2 million, or $0.49 per share, that analysts had expected. The company attributed the wider-than-expected loss to increased research and development expenses as it advances its pipeline of antiviral drug candidates.

  • Atea Pharmaceuticals reported its Q1 2026 financial results on Thursday, March 5, 2026.

The players

Atea Pharmaceuticals

A clinical-stage biopharmaceutical company focused on developing oral antiviral therapies, including a potential COVID-19 treatment.

Got photos? Submit your photos here. ›

The takeaway

While Atea Pharmaceuticals' stock price rose on the earnings news, the company's wider-than-expected loss raises questions about the progress of its drug development efforts. Investors will be closely watching for updates on the company's pipeline, particularly its potential COVID-19 treatment, in the coming quarters.